Slide 1: Financial Results for FY2025 Q3
Financial Results for FY2025 Q3 Ended September 30, 2025 November 11, 2025 Junya Suzuki Chairman of the Board and Group CEO Nissha Co., Ltd.
Slide 2: Highlights
Highlights FY2025 Q3 Results (9 months) Tailwinds Industrial Materials: Steady demand continued, mass production of new mobility products (exterior) started in Q3 Devices: The impact of decline in sales was mitigated by the factory consolidation, productivity improvement progressed Medical T
Slide 3: FY2025 Q3 (9 months) Results
FY2025 Q3 (9 months) Results （Millions of JPY） 2024 Q3 2025 Q3 Results Results YoY Net Sales 148,402 145,270 -2.1% Industrial Materials 55,314 57,074 +3.2% Devices 53,380 43,826 -17.9% Medical Technologies 33,638 35,047 +4.2% Others 6,068 9,322 +53.6% Of which, Pharmaceuticals 1,337 5,088 +280.5% Op
Slide 4: FY2025 Q3 (3 months) Results
FY2025 Q3 (3 months) Results （Millions of JPY） 2024 Q3 2025 Q2 2025 Q3 Results Results Results YoY QoQ Net Sales 48,740 49,606 48,221 -1.1% -2.8% Industrial Materials 18,094 18,785 19,504 +7.8% +3.8% Devices 17,106 16,193 14,074 -17.7% -13.1% Medical Technologies 11,613 11,510 11,588 -0.2% +0.7% Oth
Slide 5: Industrial Materials: FY2025 Q3 Results, Q4 Forecast
Industrial Materials: FY2025 Q3 Results, Q4 Forecast Quarterly net sales and operating profit margin ■ Sustainable Materials ■Decoration (Mobility) (Metallized paper and others) ● Operating profit margin Q3 Results (Forex: JPY145/$) ■Decoration (Home appliances and others) Decoration: Steady dem
Slide 6: Industrial Materials: Operating profit analysis
Industrial Materials: Operating profit analysis Q3 Results (QoQ): Production start-up costs for new mobility products (exterior) put pressure on profit Q4 Forecast (QoQ): Decrease in profit due to a demand decline (mainly for sustainable materials) (Billions of JPY) 2025 Q2 Q3 Q4 Assumed 0.05 Fo
Slide 7: Industrial Materials: 2026 Outlook
Industrial Materials: 2026 Outlook Net sales 2025 Forecast 2026 Outlook Net sales for new mobility products (exterior) (Forex: ¥146/$) (Forex: ¥140/$) (Billions of JPY) （億円） German OEM (Headlights) ¥74.3 billion ¥77.0‐80.0 billion 0.5 3.0 Europe region: Full volume production begins in Germany O
Slide 8: Devices: FY2025 Q3 Results, Q4 Forecast
Devices: FY2025 Q3 Results, Q4 Forecast Quarterly net sales and operating profit margin ■ Handheld terminals (logistics related), Mobility, Gas sensors and others ■ Tablet devices ■ Smartphones ● Operating profit margin Q3 Results (Forex: JPY145/$) （Millions of JPY） Tablet devices: Reactionary d
Slide 9: Devices: Operating profit analysis
Devices: Operating profit analysis Q3 Results (QoQ): Although production operation has been improved, sharp demand decrease for gaming devices and mobility put pressure on profitability Q4 Forecast (QoQ): Profit increased due to the improvement of product mix of tablet devices (Billions of JPY)
Slide 10: Devices: 2026 Outlook
Devices: 2026 Outlook Net sales 2025 Forecast 2026 Outlook Net sales for tablet devices (Forex: ¥146/$) (Forex: ¥140/$) (Billions of JPY) ¥58.0 billion ¥50.0‐53.0 billion 39.5 Operating profit margin Net sales 2025 Forecast 2026 Outlook 31.5～34.5 Incorporating fluctuation risks specific to produ
Slide 11: Medical Technologies: FY2025 Q3 Results, Q4 Forecast
Medical Technologies: FY2025 Q3 Results, Q4 Forecast Quarterly net sales and operating profit margin ■Business media ●Operating profit margin ■Medical devices (Own brand) ■Medical devices (CDMO) Q3 Results (Forex: JPY145/$) 00 （百万円）of JPY） （Millions Medical devices (CDMO): Demand stagnated due t
Slide 12: Medical Technologies: Operating profit analysis
Medical Technologies: Operating profit analysis Q3 Results (QoQ): Stagnated demand for the medical devices CDMO put pressure on profit Q4 Forecast (QoQ): Demand recovery expected for the medical devices CDMO (Billions of JPY) 0.1 0.75 0.25 0.1 0.6 ・Gain on sale of 0.55 inactive assets -0.15 ・Eli
Slide 13: Medical Technologies: 2026 Outlook
Medical Technologies: 2026 Outlook Net sales 2025 Forecast 2026 Outlook Net sales for Medical devices CDMO (Forex: ¥146/$) (Forex: ¥140/$) (Billions of JPY) ¥46.0 billion ¥46.0‐47.0 billion 2.0 Net sales Operating profit margin Product demand 27.3 2025 Forecast 2026 Outlook increased by 7.5% YoY
Slide 14: Medical Devices CDMO: Expanding of Pipeline Programs
Medical Devices CDMO: Expanding of Pipeline Programs Numerous programs in our pipeline is enabling growth for the medium term Programs in Pipeline (as of Oct 2025) Sales Contribution by Programs in Pipeline ■Expected contribution by programs in pipeline Total sales * (Billions of JPY) Current ■Exi
Slide 15: Others: FY2025 Q3 Results, Q4 Forecast
Others: FY2025 Q3 Results, Q4 Forecast Quarterly net sales and operating profit margin ■Information and Communication, etc. Q3 Results (Forex: JPY145/$) ■Pharmaceuticals, etc. Pharmaceuticals: Solid demand, ■ OTC Pharmaceutical CDMO (Shigaken Pharm.) some part of demand postponed to 4,000 3,678 Q
Slide 16: Update on OTC Pharmaceutical CDMO
Update on OTC Pharmaceutical CDMO Expansion of orders Decided to invest in expanding production Enhanced recognition and capacity credibility through integration From one-factory to two-factories into Nissha Group Converting the Tsu factory (cleanroom specification) of Increase in fixed
Slide 17: FY2025 Plan
FY2025 Plan (Millions of JPY) Previous Plan (August 6) Revised Plan (November 11) FY2025 FY2025 FY2025 FY2025 FY2025 FY2025 Full-year Full-year H1 H2 H1 H2 Plan Plan Results Plan Results Plan Net sales 190,800 97,049 93,751 191,300 97,049 94,251 Industrial Materials 74,300 37,570 36,730 74,300 37,57
Slide 18: (Reference) Capital investment, Depreciation and amortization, M&A investment, R&D (FY2025)
(Reference) Capital investment, Depreciation and amortization, M&A investment, R&D (FY2025) (Millions of JPY) Q1 Results Q2 Results Q3 Results Capital investment 3,033 3,413 2,728 Depreciation and 2,506 2,464 2,689 amortization M&A investment 9,500 291 0 R&D 1,034 1,051 1,033 ©2025 Nissha Group 18
Slide 19: Cautionary note on forward-looking information
Among the information included in this presentation and provided at investor briefings and conferences, performance targets, plans, outlooks, strategies and other information that is not constituted of actual past facts, is information that has been judged reasonable by the managers of the Company b